

Index to volume 62

Author index

A

- Aarbakke J (*see* Otterness et al). 1997;62:60-73
 Abernethy DR, Woosley RL. 1998 ASCPT Clinical Pharmacology Curriculum Review Course. 1997;62:694
 — (*see* Donahue et al). 1997;62:572-7
 Adams S (*see* Sarich et al). 1997;62:21-8
 Adedoyin A (*see* Arns et al). 1997;62:527-37
 — (*see* Frye et al). 1997;62:365-76
 Affrime MB (*see* Huhn et al). 1997;62:171-80
 Agneter E (*see* Müller et al). 1997;62:165-70
 Aitken JW (*see* Jorga et al). 1997;62:300-10
 Albinni S (*see* Jilma et al). 1997;62:562-8
 Al-Sayegh F (*see* Sarich et al). 1997;62:21-8
 Anichini R (*see* Sironi et al). 1997;62:194-202
 Appel S, Kumle A, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT₄ receptor agonist, in a model of slow colonic transit. 1997;62:546-55
 Apseloff G, Wayne JK, Gerber N. Reliability of screening procedures in identifying subjects suitable for enrollment in clinical pharmacology studies. 1997;62:113-4 (Letter reply)
 Arns PA, Adedoyin A, DiBisceglie AM, Waggoner JG, Hoffnagle JH, Wilkinson GR, Branch RA. Mephenytoin disposition and serum bile acids as indexes of hepatic function in chronic viral hepatitis. 1997;62:527-37
 Asmus MJ, Weinberger MM, Milavetz G, Marshik P, Teresi ME, Hendeles L. Apparent decrease in population clearance of theophylline: implications for dosage. 1997;62:483-9

B

- Badoual J (*see* Pariente-Khayat et al). 1997;62:377-83
 Barbhaiya RH (*see* Srinivas et al). 1997;62:408-16
 Bazoon M (*see* Naranjo et al). 1997;62:209-24
 — (*see* Sproule et al). 1997;62:29-40
 Becker PK (*see* Ferguson et al). 1997;62:203-8
 Bekersky I (*see* Floren et al). 1997;62:41-9
 Benet LZ (*see* Floren et al). 1997;62:41-9
 — (*see* Lown et al). 1997;62:248-60
 Benin A (*see* Lewis et al). 1997;62:464-75
 Benjamin IS (*see* Brookman et al). 1997;62:272-8
 Benowitz NL. Birthing of clinical pharmacologists. 1997;62:587-91 (Commentary)
 — (*see* Gourlay and Benowitz). 1997;62:453-63
 Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. 1997;62:643-51
 — (*see* Kurtz et al). 1997;62:145-56
 Bertilsson L (*see* Böttiger et al). 1997;62:384-91
 — (*see* Tybring et al). 1997;62:129-37
 Bishop FE (*see* Tran et al). 1997;62:490-504
 Blum RA (*see* Kazierad et al). 1997;62:417-25
 Bodalski J (*see* Zielinska et al). 1997;62:635-42
 Boddaert M (*see* Olbricht et al). 1997;62:311-21
 Boike SC (*see* Kazierad et al). 1997;62:417-25
 Bolanowski W (*see* Zielinska et al). 1997;62:635-42
 Boon NA (*see* Masumori et al). 1997;62:327-33

- Botta L (*see* Racine-Poon et al). 1997;62:675-90
 Böttiger Y, Tybring G, Götharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. 1997;62:384-91
 — (*see* Tybring et al). 1997;62:129-37
 Bottorff MB (*see* Ujhelyi et al). 1997;62:117-28
 Boulton DW, Fawcett JP. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. 1997;62:138-44
 Bracht C (*see* Stitsch et al). 1997;62:538-45
 Branch RA (*see* Arns et al). 1997;62:527-37
 — (*see* Frye et al). 1997;62:365-76
 Branum E (*see* Otterness et al). 1997;62:60-73
 Brater DC (*see* Ferguson et al). 1997;62:203-8
 Breimer DD (*see* Tuk et al). 1997;62:444-52
 Bremner KE (*see* Naranjo et al). 1997;62:209-24
 Bronsky E, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. 1997;62:556-61
 Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F. Pharmacokinetics of valsartan in patients with liver disease. 1997;62:272-8
 — (*see* Lefèvre et al). 1997;62:50-9
 Brøsen K (*see* Jeppesen et al). 1997;62:279-86
 Brown M (*see* Stein et al). 1997;62:436-43
 Brown MB (*see* Lown et al). 1997;62:248-60
 Brunner M (*see* Müller et al). 1997;62:165-70
 — (*see* Müller et al). 1997;62:293-9
 Bruno R, Vivier N, Montay G, Le Liboux A, Powe LK, Delumeau J-C, Rhodes GR. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. 1997;62:518-26
 Burgdorff T (*see* Müller et al). 1997;62:165-70

C

- Calabresi P (*see* Vestal and Calabresi). 1997;62:361-4 (Commentary)
 Cao G (*see* Samara et al). 1997;62:426-35
 — (*see* Wong et al). 1997;62:157-64
 Caraco Y (*see* Levy et al). 1997;62:6-14
 Carrilho AJF, Medina WL, Nakandakare ER, Quintão ECR. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. 1997;62:82-8
 Carruthers SG (*see* Gupta and Carruthers). 1997;62:322-6
 Casner PR. Self-medication. 1997;62:355 (Letter)
 Cerimele BJ (*see* Bergstrom et al). 1997;62:643-51
 — (*see* Kurtz et al). 1997;62:145-56
 Chang TW (*see* Racine-Poon et al). 1997;62:675-90
 Chevrel J (*see* Marquet et al). 1997;62:569-71
 Christians U (*see* Olbricht et al). 1997;62:311-21
 Close P (*see* Lefèvre et al). 1997;62:50-9
 Cohen AF (*see* Tuk et al). 1997;62:444-52
 Cotter G, Weissgarten J, Metzker E, Moshkovitz Y, Litinski I, Tavori U, Perry C, Zaidenstein R, Golik A. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. 1997;62:187-93
 Coyle TE (*see* Lehmann et al). 1997;62:225-9
 Crémier O (*see* Pariente-Khayat et al). 1997;62:377-83
 Crosby RD (*see* Halikas et al). 1997;62:89-105
 Cutler DL (*see* Huhn et al). 1997;62:171-80

July, pp. 1-116; August, pp. 117-236; September, pp. 237-360; October, pp. 361-480; November, pp. 481-582; December, pp. 583-718. Index to the ASCPT meeting abstracts is located in the February issue.

D

- Dally S (*see* Rizzo et al). 1997;62:505-9
Danhof M (*see* Tuk et al). 1997;62:444-52
Darj E (*see* Wadelius et al). 1997;62:400-7
d'Adhis P (*see* Pariente-Khayat et al). 1997;62:377-83
— (*see* Tran et al). 1997;62:490-504
Davis FM (*see* Racine-Poon et al). 1997;62:675-90
Dean R (*see* Samara et al). 1997;62:426-35
De Carolis MP (*see* Romagnoli et al). 1997;62:181-6
Deckers CLP, Hekster YA, Keyser A, Meinardi H, Renier WO.
Drug load in clinical trials: a neglected factor. 1997;62:592-5
(Commentary)
de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN.
Tobramycin population pharmacokinetics in neonates.
1997;62:392-9
Delumeau J-C (*see* Bruno et al). 1997;62:518-26
de Mey C. Reliability of screening procedures in identifying subjects suitable for enrollment in clinical pharmacology studies. 1997;62:112-3 (Letter)
DiBisceglie AM (*see* Arns et al). 1997;62:527-37
DiGirolamo A (*see* O'Neil et al). 1997;62:261-71
Dionne RA (*see* Troullos et al). 1997;62:74-81
Dolbeault S (*see* Rizzo et al). 1997;62:505-9
Doll R (*see* Olbricht et al). 1997;62:311-21
Donahue SR, Flockhart DA, Abernethy DR, Ko J-W. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. 1997;62:572-7
Dorner G (*see* Müller et al). 1997;62:165-70
— (*see* Müller et al). 1997;62:293-9
Dressler D (*see* Floren et al). 1997;62:61-9
Duboin M-P (*see* Russo et al). 1997;62:15-20
Duval M (*see* Lefèvre et al). 1997;62:50-9

E

- Eichler HG (*see* Jilma et al). 1997;62:562-8
— (*see* Müller et al). 1997;62:165-70
— (*see* Müller et al). 1997;62:293-9
Eisenhauer T (*see* Olbricht et al). 1997;62:311-21
Etheredge R (*see* Kazierad et al). 1997;62:417-25

F

- Farr SJ (*see* Ward et al). 1997;62:596-609
Fawcett JP (*see* Boulton and Fawcett). 1997;62:138-44
Ferguson JA, Sundblad KJ, Becker PK, Gorski JC, Rudy DW, Brater DC. Role of duration of diuretic effect in preventing sodium retention. 1997;62:203-8
Ferrannini E (*see* Sironi et al). 1997;62:194-202
Ferreira I (*see* Sica et al). 1997;62:610-8
Flesch G (*see* Brookman et al). 1997;62:272-8
Flockhart DA (*see* Donahue et al). 1997;62:572-7
Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. 1997;62:41-9
Foot E (*see* Sironi et al). 1997;62:194-202
Ford NF (*see* Sica et al). 1997;62:610-8
Fotteler B (*see* Jorga et al). 1997;62:300-10
Frank W (*see* Racine-Poon et al). 1997;62:675-90
Frenne G (*see* Wadelius et al). 1997;62:400-7
Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. 1997;62:365-76
Furusho K (*see* Odani et al). 1997;62:287-92

G

- Gallini F (*see* Romagnoli et al). 1997;62:181-6

- Gallo J (*see* Huhn et al). 1997;62:171-80
Gastaldelli A (*see* Sironi et al). 1997;62:194-202
Gauron S (*see* Lefèvre et al). 1997;62:50-9
Gehr TWB (*see* Sica et al). 1997;62:610-8
Gendrel D (*see* Pariente-Khayat et al). 1997;62:377-83
Gerber N (*see* Apseloff et al). 1997;62:113-4 (Letter reply)
Giannini R (*see* Romagnoli et al). 1997;62:181-6
Gilfix BM (*see* O'Neil et al). 1997;62:261-71
Gillard J-M (*see* Tran et al). 1997;62:490-504
Girre C (*see* Rizzo et al). 1997;62:505-9
Gleason C (*see* Srinivas et al). 1997;62:408-16
Gleiter CH (*see* Jilma et al). 1997;62:562-8
Goldberg MJ (*see* Bergstrom et al). 1997;62:643-51
— (*see* Kurtz et al). 1997;62:145-56
Goldstein J (*see* Sarich et al). 1997;62:21-8
Golik A (*see* Cotter et al). 1997;62:187-93
Gonyo G (*see* Huhn et al). 1997;62:171-80
Gorski JC (*see* Ferguson et al). 1997;62:203-8
Götharson E (*see* Böttiger et al). 1997;62:384-91
Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. 1997;62:453-63
Granit L (*see* Levy et al). 1997;62:6-14
Granneman GR (*see* Samara et al). 1997;62:426-35
— (*see* Wong et al). 1997;62:157-64
Graves NM (*see* Halikas et al). 1997;62:89-105
Gray J, Lewis L, Nierenberg D. Clinical pharmacology education in primary care residency programs. 1997;62:237-40 (Commentary)
Greene DS (*see* Srinivas et al). 1997;62:408-16
Guerreiro D (*see* Bronsky et al). 1997;62:556-61
Guo W (*see* Lown et al). 1997;62:248-60
Gupta A, Carruthers SG. Familial studies of heritability of α_1 -adrenergic receptor responsiveness in superficial veins. 1997;62:322-6
Gyax D (*see* Racine-Poon et al). 1997;62:675-90

H

- Hakusui H (*see* Tanaka et al). 1997;62:619-28
Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. 1997;62:89-105
Hammett JL (*see* Sica et al). 1997;62:610-8
Hargreaves KM (*see* Troullos et al). 1997;62:74-81
Hashimoto Y (*see* Odani et al). 1997;62:287-92
Hatcher BL (*see* Bergstrom et al). 1997;62:643-51
Hattori H (*see* Odani et al). 1997;62:287-92
Hebert MF (*see* Floren et al). 1997;62:41-9
Hekster YA (*see* Deckers et al). 1997;62:592-5 (Commentary)
Hendeles L (*see* Asmus et al). 1997;62:483-9
Herrmann N (*see* Özdemiir et al). 1997;62:334-47
Hirano T, Oka K, Takeuchi H, Kozaki K, Matsuno N, Nagao T, Kozaki M, Ichikawa M, Yoshida M, Umezawa Y, Hirata M, Oh-i T, Koga M. Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy. 1997;62:652-64
Hirata M (*see* Hirano et al). 1997;62:652-64
Hispard E (*see* Rizzo et al). 1997;62:505-9
Hoffnagle JH (*see* Arns et al). 1997;62:527-37
Hsiao H-I (*see* Lown et al). 1997;62:248-60
Huhn RD, Radwanski E, Gallo J, Affrime MB, Sabo R, Gonyo G, Monge A, Cutler DL. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. 1997;62:171-80
Hurteau TE (*see* Lehmann et al). 1997;62:225-9

I

- Ichikawa M (see Hirano et al). 1997;62:652-64
Ilan Y (see Levy et al). 1997;62:6-14
Ilson B (see Kazierad et al). 1997;62:417-25
Inui K-i (see Odani et al). 1997;62:287-92
Ishizaki T (see Tanaka et al). 1997;62:619-28
Iven H (see Otterness et al). 1997;62:60-73

J

- Jansen B (see Müller et al). 1997;62:165-70
Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. 1997;62:279-86
Jilma B, Voltmann J, Albinni S, Stohlawetz P, Schwarzingier I, Gleiter CH, Rauch A, Eichler HG, Wagner OF. Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans. 1997;62:562-8
Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. 1997;62:300-10
Jorkasky DK (see Kazierad et al). 1997;62:417-25

K

- Kalhorn T (see Sarich et al). 1997;62:21-8
Kalow W (see Özdemir et al). 1997;62:334-47
Kamphuisen HAC (see Tuk et al). 1997;62:444-52
Kaneko S (see Tanaka et al). 1997;62:619-28
Kantola T (see Kivistö et al). 1997;62:348-54
Karlsson MO, Wade JR, Loumaye E, Munafo A. A population model for the follicular growth in women treated with follicle stimulating hormone. 1997;62:665-74
Kaukonen K-M, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. 1997;62:510-7
Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. 1997;62:417-25
Kemp B (see Tuk et al). 1997;62:444-52
Kemp JP (see Bronsky et al). 1997;62:556-61
Keyser A (see Deckers et al). 1997;62:592-5 (Commentary)
Kikuta C (see Müller et al). 1997;62:293-9
Killian A (see Samara et al). 1997;62:426-35
Kim JH (see Sütsch et al). 1997;62:538-45
Kiowski W (see Sütsch et al). 1997;62:538-45
Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. 1997;62:348-54
— (see Villikka et al). 1997;62:629-34
Klemetsdal B (see Otterness et al). 1997;62:60-73
Kliem V (see Olbricht et al). 1997;62:311-21
Ko J-W (see Donahue et al). 1997;62:572-7
Koga M (see Hirano et al). 1997;62:652-64
Koren G. Bias against the null hypothesis in maternal-fetal pharmacology and toxicology. 1997;62:1-5 (Commentary)
Kozaki K (see Hirano et al). 1997;62:652-64
Kozaki M (see Hirano et al). 1997;62:652-64
Krekler M (see Olbricht et al). 1997;62:311-21
Kumle A (see Appel et al). 1997;62:546-55
Kunze KL (see Tran et al). 1997;62:490-504
Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. 1997;62:145-56

L

- Labroo R (see Tran et al). 1997;62:490-504
Lachâtre G (see Marquet et al). 1997;62:569-71

- Lamberg TS (see Kivistö et al). 1997;62:348-54
Lang CC (see Stein et al). 1997;62:436-43
Lasagna L (see Manocchia and Lasagna). 1997;62:241-7 (Commentary)
Lavignasse P (see Marquet et al). 1997;62:569-71
Lee JW (see Floren et al). 1997;62:41-9
Lefèvre G, Duval M, Gauron S, Brookman LJ, Rolan PE, Morris TM, Piraino AJ, Morgan JM, Palmisano M, Close P. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. 1997;62:50-9
Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. 1997;62:225-9
Leibowich I (see Levy et al). 1997;62:6-14
Leichtman AB (see Lown et al). 1997;62:248-60
Le Liboux A (see Bruno et al). 1997;62:518-26
Lennard L (see Lewis et al). 1997;62:464-75
— (see Otterness et al). 1997;62:60-73
Lepage F (see Tran et al). 1997;62:490-504
Leverge R (see Rizzo et al). 1997;62:505-9
Levey BA (see Lewis and Levey). 1997;62:694-5
Levy M, Leibowich I, Zylber-Katz E, Ilan Y, Granit L, Svir S, Caraco Y. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus. 1997;62:6-14
Levy RH (see Tran et al). 1997;62:490-504
Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW. Olsalazine- and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. 1997;62:464-75
—, Levey BA. 1998 ASCPT workshop on Clinical Pharmacology in Primary Care Residency Education. 1997;62:694-5
— (see Gray et al). 1997;62:237-40 (Commentary)
Liou RS (see Racine-Poon et al). 1997;62:675-90
Litinski I (see Cotter et al). 1997;62:187-93
Lloyd P (see Brookman et al). 1997;62:272-8
— (see Ward et al). 1997;62:596-609
Locke C (see Samara et al). 1997;62:426-35
Loumaye E (see Karlsson et al). 1997;62:665-74
Lown KS, Mayo RR, Leichtman AB, Hsiao H-I, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (*mdr1*) in interpatient variation in the oral bioavailability of cyclosporine. 1997;62:248-60
Luurila H (see Villikka et al). 1997;62:629-34

M

- Mack RJ (see Wong et al). 1997;62:157-64
Magee S (see Sarich et al). 1997;62:21-8
Mangold B (see Olbricht et al). 1997;62:311-21
Manocchia M, Lasagna L. Issues in pharmaceutical lotteries: the case of interferon beta-1b. 1997;62:241-7 (Commentary)
Marino MR (see Sica et al). 1997;62:610-8
Markel ML (see Ujhelyi et al). 1997;62:117-28
Marquet P, Chevrel J, Lavignasse P, Merle L, Lachâtre G. Buprenorphine withdrawal syndrome in a newborn. 1997;62:569-71
Marshik P (see Asmus et al). 1997;62:483-9
Martin DE (see Kazierad et al). 1997;62:417-25
Mascher H (see Müller et al). 1997;62:293-9
Masumori S, Newby DE, Strachan FE, Boon NA, Webb DJ. Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans. 1997;62:327-33
Mather GG (see Tran et al). 1997;62:490-504
Mather LE (see Ward et al). 1997;62:596-609
Matsuno N (see Hirano et al). 1997;62:652-64
Matzke GR (see Frye et al). 1997;62:365-76
Mayo RR (see Lown et al). 1997;62:248-60

- Medina WL (see Carrilho et al). 1997;62:82-8
 Meier R (see Appel et al). 1997;62:546-55
 Meinardi H (see Deckers et al). 1997;62:592-5 (Commentary)
 Mekki Q (see Floren et al). 1997;62:41-9
 Merle L (see Marquet et al). 1997;62:569-71
 Metzko E (see Cotter et al). 1997;62:187-93
 Milavetz G (see Asmus et al). 1997;62:483-9
 Monge A (see Huhn et al). 1997;62:171-80
 Montay G (see Bruno et al). 1997;62:518-26
 Morgan JM (see Lefèvre et al). 1997;62:50-9
 Morris TM (see Lefèvre et al). 1997;62:50-9
 Moshkovitz Y (see Cotter et al). 1997;62:187-93
 Mouton JW (see de Hoog et al). 1997;62:392-9
 Müller M, Burgdorff T, Jansen B, Singer EA, Agneter E, Dörner G, Brunner M, Eichler HG. In vivo drug-response measurements in target tissues by microdialysis. 1997;62:165-70
 —, Mascher H, Kikuta C, Schäfer S, Brunner M, Dörner G, Eichler HG. Diclofenac concentrations in defined tissue layers after topical administration. 1997;62:293-9
 Mullins F (see Brookman et al). 1997;62:272-8
 Munafò A (see Karlsson et al). 1997;62:665-74

N

- Nagao T (see Hirano et al). 1997;62:652-64
 Nakandakare ER (see Carrilho et al). 1997;62:82-8
 Naranjo CA, Bremner KE, Bazoon M, Turksen JB. Using fuzzy logic to predict response to citalopram in alcohol dependence. 1997;62:209-24
 — (see Özdemir et al). 1997;62:334-47
 — (see Sproule et al). 1997;62:29-40
 Nelson R (see Stein et al). 1997;62:436-43
 Nelson S (see Sarich et al). 1997;62:21-8
 Neuvonen PJ (see Kaukonen et al). 1997;62:510-7
 — (see Kivistö et al). 1997;62:348-54
 — (see Villikka et al). 1997;62:629-34
 Newby DE (see Masumori et al). 1997;62:327-33
 Newman N (see Lehmann et al). 1997;62:225-9
 Nielsen T (see Jorga et al). 1997;62:300-10
 Nierenberg D (see Gray et al). 1997;62:237-40 (Commentary)
 — (see Lewis et al). 1997;62:464-75
 Niewiarowski W (see Zielińska et al). 1997;62:635-42

O

- Oberý J (see Tuk et al). 1997;62:444-52
 O'Brien J (see Otterness et al). 1997;62:60-73
 Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K-i. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. 1997;62:287-92
 O'Grady P (see Olbricht et al). 1997;62:311-21
 Oh-i T (see Hirano et al). 1997;62:652-64
 Ohkubo T (see Tanaka et al). 1997;62:619-28
 Oka K (see Hirano et al). 1997;62:652-64
 Okikawa JK (see Ward et al). 1997;62:596-609
 Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. 1997;62:311-21
 Olive G (see Pariente-Khayat et al). 1997;62:377-83
 — (see Tran et al). 1997;62:490-504
 Olkkola KT (see Kaukonen et al). 1997;62:510-7
 O'Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow? 1997;62:261-71
 Otani K (see Tanaka et al). 1997;62:619-28
 Otsuki Y (see Odani et al). 1997;62:287-92

- Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. 1997;62:60-73
 — (see Lewis et al). 1997;62:464-75
 Özdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. 1997;62:334-47

P

- Palmer KR (see Brookman et al). 1997;62:272-8
 Palmisano M (see Lefèvre et al). 1997;62:50-9
 Papacci P (see Romagnoli et al). 1997;62:181-6
 Pariente-Khayat A, Rey E, Gendrel D, Vauzelle-Kervroëdan F, Crémier O, d'Athis P, Badoual J, Olive G, Pons G. Isoniazid acetylation metabolic ratio during maturation in children. 1997;62:377-83
 Park-Hah JO (see Otterness et al). 1997;62:60-73
 Pearson VL (see Halikas et al). 1997;62:89-105
 Peck CC (see Tuk et al). 1997;62:444-52
 Pecori N (see Sironi et al). 1997;62:194-202
 Perry C (see Cotter et al). 1997;62:187-93
 Pieters MSM (see Tuk et al). 1997;62:444-52
 Piraino AJ (see Lefèvre et al). 1997;62:50-9
 Pons G (see Pariente-Khayat et al). 1997;62:377-83
 — (see Tran et al). 1997;62:490-504
 Porter JA (see Frye et al). 1997;62:365-76
 Powe LK (see Bruno et al). 1997;62:518-26
 Prins JM, Weverling GJ, van Ketel RJ, Speelman P. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. 1997;62:106-11

Q

- Quintão ECR (see Carrilho et al). 1997;62:82-8

R

- Racine-Poon A, Botta L, Chang TW, Davis FM, Gyga D, Liou RS, Rohane P, Staehelin T, van Steijn AMP, Frank W. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. 1997;62:675-90
 Radwanski E (see Huhn et al). 1997;62:171-80
 Rane A (see Wadelius et al). 1997;62:400-7
 Rasmussen BB (see Jeppesen et al). 1997;62:279-86
 Rauch A (see Jilma et al). 1997;62:562-8
 Rebowski G (see Zielińska et al). 1997;62:635-42
 Reed K (see Özdemir et al). 1997;62:334-47
 Reidenberg J (see Reidenberg and Reidenberg). 1997;62:230-2
 Reidenberg MM, Reidenberg J. Annual report to the Editorial Advisory Council, 1996. 1997;62:230-2
 Reiss TF (see Bronsky et al). 1997;62:556-61
 Renier WO (see Deckers et al). 1997;62:592-5 (Commentary)
 Rey E (see Pariente-Khayat et al). 1997;62:377-83
 — (see Tran et al). 1997;62:490-504
 Rhodes GR (see Bruno et al). 1997;62:518-26
 Rizzo N, Hispard E, Dolbeault S, Dally S, Leverge R, Girre C. Impact of long-term ethanol consumption on CYP1A2 activity. 1997;62:505-9
 Roberts JP (see Floren et al). 1997;62:41-9
 Rohane P (see Racine-Poon et al). 1997;62:675-90
 Rolan PE (see Brookman et al). 1997;62:272-8
 — (see Lefèvre et al). 1997;62:50-9
 Roll K (see Ujhelyi et al). 1997;62:117-28

- Romagnoli C, Zecca E, Papacci P, De Carolis MP, Giannini R, Gallini F, Tortorolo G. Furosemide does not prevent indomethacin-induced renal side effects in preterm infants. 1997;62:181-6
Rossi SJ (*see* Lown et al). 1997;62:248-60
Rousseau M (*see* Tran et al). 1997;62:490-504
Rubsamen RM (*see* Ward et al). 1997;62:596-609
Rudy DW (*see* Ferguson et al). 1997;62:203-8
Russo H, Simon N, Duboin M-P, Urien S. Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries. 1997;62:15-20
Ryokawa Y (*see* Tanaka et al). 1997;62:619-28

S

- Sabo R (*see* Huhn et al). 1997;62:171-80
Samara E, Cao G, Locke C, Granneman GR, Dean R, Killian A. Population analysis of the pharmacokinetics and pharmacodynamics of seratroast in patients with mild to moderate asthma. 1997;62:426-35
Sarich T, Kalhorn T, Magee S, Al-Sayegh F, Adams S, Slaterry J, Goldstein J, Nelson S, Wright J. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. 1997;62:21-8
Schäfer S (*see* Müller et al). 1997;62:293-9
Schmiedlin-Ren P (*see* Lown et al). 1997;62:248-60
Schmiegelow K (*see* Otterness et al). 1997;62:60-73
Schoemaker RC (*see* de Hoog et al). 1997;62:392-9
— (*see* Tuk et al). 1997;62:444-52
Schur M (*see* Ujhelyi et al). 1997;62:117-28
Schuster A (*see* Srinivas et al). 1997;62:408-16
Schuster JA (*see* Ward et al). 1997;62:596-609
Schwarzinger I (*see* Jilma et al). 1997;62:562-8
Sedek G (*see* Jorga et al). 1997;62:300-10
Seghieri G (*see* Sironi et al). 1997;62:194-202
Sellers EM (*see* Özdemir et al). 1997;62:334-47
Shulman KI (*see* Sproule et al). 1997;62:29-40
Shyu WC (*see* Srinivas et al). 1997;62:408-16
Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TWB, Ford NF. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. 1997;62:610-8
Simon N (*see* Russo et al). 1997;62:15-20
Singer EA (*see* Müller et al). 1997;62:165-70
Sioufi A (*see* Brookman et al). 1997;62:272-8
Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. 1997;62:194-202
Slattery J (*see* Sarich et al). 1997;62:21-8
Speelman P (*see* Prins et al). 1997;62:106-11
Spence JD. Informing the public. 1997;62:579 (Letter reply)
Sproule BA, Bazoon M, Shulman KI, Turksen IB, Naranjo CA. Fuzzy logic pharmacokinetic modeling: application to lithium concentration prediction. 1997;62:29-40
Srinivas NR, Shyu WC, Gleason C, Schuster A, Greene DS, Barbhuiya RH. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. 1997;62:408-16
Staehelin T (*see* Racine-Poon et al). 1997;62:675-90
Stańczyk A (*see* Zielińska et al). 1997;62:635-42
Stein CM, Lang CC, Nelson R, Brown M, Wood AJJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. 1997;62:436-43
Stewart J (*see* Ujhelyi et al). 1997;62:117-28
Stohlawetz P (*see* Jilma et al). 1997;62:562-8
Strachan FE (*see* Masumori et al). 1997;62:327-33
Sugawara K (*see* Tanaka et al). 1997;62:619-28
Sundblad KJ (*see* Ferguson et al). 1997;62:203-8

- Sütsch G, Kim JH, Bracht C, Kiowski W. Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance. 1997;62:538-45
Suzuki A (*see* Tanaka et al). 1997;62:619-28
Sviri S (*see* Levy et al). 1997;62:6-14
Swayne JK (*see* Apseloff et al). 1997;62:113-4 (Letter reply)
Szumlanski CL (*see* Lewis et al). 1997;62:464-75
— (*see* Otterness et al). 1997;62:60-73

T

- Takeuchi H (*see* Hirano et al). 1997;62:652-64
Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Hakusui H, Yamamori S, Ishizaki T. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. 1997;62:619-28
Tavori U (*see* Cotter et al). 1997;62:187-93
Tenero DM (*see* Kazierad et al). 1997;62:417-25
Teresi ME (*see* Asmus et al). 1997;62:483-9
Thummel KE (*see* Tran et al). 1997;62:490-504
Tortorolo G (*see* Romagnoli et al). 1997;62:181-6
Trager WF (*see* Tran et al). 1997;62:490-504
Tran A, Rey EA, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin J-M, Lepage F, Levy RH. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. 1997;62:490-504
Troullos E, Hargreaves KM, Dionne RA. Ibuprofen elevates immunoreactive β -endorphin levels in humans during surgical stress. 1997;62:74-81
Tsoukas CM (*see* O'Neil et al). 1997;62:261-71
Tuk B, Oberyé JLL, Pieters MSM, Schoemaker RC, Kemp B, van Gerven J, Danhof M, Kamphuisen HAC, Cohen AF, Breimer DD, Peck CC. Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalographic and saccadic eye movements in predicting improvement of sleep. 1997;62:444-52
Turgeon DK (*see* Lown et al). 1997;62:248-60
Turksen IB (*see* Naranjo et al). 1997;62:209-24
— (*see* Sproule et al). 1997;62:29-40
Tybring G, Böttiger Y, Widén J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. 1997;62:129-37
— (*see* Böttiger et al). 1997;62:384-91

U

- Ujhelyi MR, Bottorff MB, Schur M, Roll K, Zhang H, Stewart J, Markel ML. Aging effects on the organic base transporter and stereoselective renal clearance. 1997;62:117-28
Umezawa Y (*see* Hirano et al). 1997;62:652-64
Urien S (*see* Russo et al). 1997;62:15-20
Urquhart J. Comparative regulation of drug and aircraft development: Lessons for regulatory reform? 1997;62:583-6 (Commentary)
Uwai Y (*see* Odani et al). 1997;62:287-92

V

- van den Anker JN (*see* de Hoog et al). 1997;62:392-9
van Gerven J (*see* Tuk et al). 1997;62:444-52
van Ketel RJ (*see* Prins et al). 1997;62:106-11
van Steijn AMP (*see* Racine-Poon et al). 1997;62:675-90
Vauzelle-Kervroëdan F (*see* Pariente-Khayat et al). 1997;62:377-83
Vestal RE. A message from the President: come to the ASCPT meeting in New Orleans, March 30–April 1, 1998. 1997;62:693-4

- , Calabresi P. Geriatric clinical pharmacologist and medical oncologist: A new partnership? 1997;62:361-4 (Commentary)
Vichi S (*see* Sironi et al). 1997;62:194-202
Villikka K, Kivistö KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. 1997;62:629-34
Vincent JC (*see* Tran et al). 1997;62:490-504
Vivier N (*see* Bruno et al). 1997;62:518-26
Vollmann J (*see* Jilma et al). 1997;62:562-8

W

- Wade JR (*see* Karlsson et al). 1997;62:665-74
Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. 1997;62:400-7
Waggoner JG (*see* Arns et al). 1997;62:527-37
Wagner OF (*see* Jilma et al). 1997;62:562-8
Wainer IW (*see* O'Neil et al). 1997;62:261-71
Wakelkamp M. Computational results may depend on personal computer processor. 1997;62:481-2 (Commentary)
Waldmeier F (*see* Brookman et al). 1997;62:272-8
Walson PD. Toxicity of lidocaine desethyl metabolites. 1997;62:579 (Letter)
Wanner C (*see* Olbricht et al). 1997;62:311-21
Ward ME, Woodhouse A, Mather LE, Farr SJ, Okikawa JK, Lloyd P, Schuster JA, Rubsamen RM. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. 1997;62:596-609
Watkins PB (*see* Lown et al). 1997;62:248-60
Webb DJ (*see* Masumori et al). 1997;62:327-33
Weinberger MM (*see* Asmus et al). 1997;62:483-9
Weiner M. Informing the public. 1997;62:578-9 (Letter)
Weinshilboum RM. A message from the Finance Committee chairperson. 1997;62:477
— (*see* Lewis et al). 1997;62:464-75
— (*see* Otterness et al). 1997;62:60-73
Weissgarten J (*see* Cotter et al). 1997;62:187-93
Weverling GJ (*see* Prins et al). 1997;62:106-11
Widén J (*see* Tybring et al). 1997;62:129-37
Wilkinson GR (*see* Arns et al). 1997;62:527-37
Wong SL, Cao G, Mack RJ, Granneman GR. Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. 1997;62:157-64
Wood AJJ (*see* Stein et al). 1997;62:436-43
Woodhouse A (*see* Ward et al). 1997;62:596-609
Woosley RL (*see* Abernethy and Woosley). 1997;62:694
Wright J (*see* Sarich et al). 1997;62:21-8
Wurden CJ (*see* Tran et al). 1997;62:490-504
Wyld PJ (*see* Brookman et al). 1997;62:272-8

X

- Xie H-G. Direct evidence for the higher frequency of *CYP2C19* allelic heterozygotes in Chinese subjects than in white subjects. 1997;62:691-2 (Letter)

Y

- Yamamori S (*see* Tanaka et al). 1997;62:619-28
Yoshida M (*see* Hirano et al). 1997;62:652-64

Z

- Zaidenstein R (*see* Cotter et al). 1997;62:187-93
Zecca E (*see* Romagnoli et al). 1997;62:181-6
Zhang H (*see* Ujhelyi et al). 1997;62:117-28
Zhang J (*see* Bronsky et al). 1997;62:556-61
Zielińska E, Niewiarowski W, Bodalski J, Stańczyk A, Bolanowski W, Rebowski G. Arylamine *N*-acetyltransferase (*NAT2*) gene mutations in children with allergic diseases. 1997;62:635-42
Zürcher G (*see* Jorga et al). 1997;62:300-10
Zylber-Katz E (*see* Levy et al). 1997;62:6-14

Subject index

A

Acetaminophen

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of *S*-mephenytoin (Sarich et al). 1997;62:21-8

Acetylation

Isoniazid acetylation metabolic ratio during maturation in children (Pariente-Khayat et al). 1997;62:377-83

N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow? (O'Neil et al). 1997;62:261-71

Acetyltransferases

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Acquired immunodeficiency syndrome

N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow? (O'Neil et al). 1997;62:261-71

Administration, inhalation

Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system (Ward et al). 1997;62:596-609

Administration, nasal

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Administration, topical

Diclofenac concentrations in defined tissue layers after topical administration (Müller et al). 1997;62:293-9

Adrenergic beta receptor agonists

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans (Boulton and Fawcett). 1997;62:138-44

Aerosol delivery; see Administration, inhalation

African Americans

Vasodilation in black Americans: attenuated nitric oxide-mediated responses (Stein et al). 1997;62:436-43

Age factors

Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects (Srinivas et al). 1997;62:408-16

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects (Wong et al). 1997;62:157-64

Aged

Geriatric clinical pharmacologist and medical oncologist: A new partnership? (Vestal and Calabresi). 1997;62:361-4 (Commentary)

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly (Jorga et al). 1997;62:300-10

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects (Wong et al). 1997;62:157-64

Aging

Aging effects on the organic base transporter and stereoselective renal clearance (Ujhelyi et al). 1997;62:117-28

AIDS; see Acquired immunodeficiency syndrome

Aircraft

Comparative regulation of drug and aircraft development: Lessons for regulatory reform? (Urquhart). 1997;62:583-6 (Commentary)

Albuterol

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans (Boulton and Fawcett). 1997;62:138-44

Alcohol

Using fuzzy logic to predict response to citalopram in alcohol dependence (Naranjo et al). 1997;62:209-24

Alcohol, ethyl

Impact of long-term ethanol consumption on CYP1A2 activity (Rizzo et al). 1997;62:505-9

Allergy; see Hypersensitivity

Almotriptan

Almotriptan (USAN List No. 400). 1997;62:698

Alniditan dihydrochloride

Alniditan dihydrochloride (USAN List No. 395). 1997;62:115

Alpha adrenergic receptors; see Receptors, adrenergic, alpha

Alphafilcon A

Alphafilcon A (USAN List No. 396). 1997;62:235

American Society for Clinical Pharmacology and Therapeutics

1998 ASCPT Clinical Pharmacology Curriculum Review Course (Abernethy and Woosley). 1997;62:694

1998 ASCPT workshop on Clinical Pharmacology in Primary Care Residency Education (Lewis and Levey). 1997;62:694-5

Future meeting dates and sites of the ASCPT. 1997;62:14, 164

A message from the Finance Committee chairperson (Weinshilboum). 1997;62:477

A message from the President: come to the ASCPT meeting in New Orleans, March 30–April 1, 1998 (Vestal). 1997;62:693-4

Nominations for awards. 1997;62:356-7

Aminoglycosides

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients (Prins et al). 1997;62:106-11

Amyotrophic lateral sclerosis

Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis (Bruno et al). 1997;62:518-26

Angiotensin II

Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans (Masumori et al). 1997;62:327-33

Anisatril

Anisatril (USAN List No. 396). 1997;62:234

Annual report

Annual report to the Editorial Advisory Council, 1996 (Reidenberg and Reidenberg). 1997;62:230-2

Antibodies, monoclonal

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis (Racine-Poon et al). 1997;62:675-90

July, pp. 1-116; August, pp. 117-236; September, pp. 237-360; October, pp. 361-480; November, pp. 481-582; December, pp. 583-718. Index to the ASCPT meeting abstracts is located in the February issue.

Anticonvulsants

Anticonvulsant usage is associated with an increased risk of procainamide hypersensitivity reactions in patients with brain tumors (Lehmann et al). 1997;62:225-9

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants (Tran et al). 1997;62:490-504

Antidepressive agents

Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects (Srinivas et al). 1997;62:408-16

Anti-inflammatory agents, non-steroidal

Diclofenac concentrations in defined tissue layers after topical administration (Müller et al). 1997;62:293-9

Argatroban

Argatroban (USAN List No. 397). 1997;62:359

Aripiprazole

Aripiprazole (USAN List No. 396). 1997;62:233

Arm

Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance (Sütsch et al). 1997;62:538-45

Arteries

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance (Sütsch et al). 1997;62:538-45

Arylamine acetyltransferases

Arylamine *N*-acetyltransferase (NAT2) gene mutations in children with allergic diseases (Zielińska et al). 1997;62:635-42

Asthma

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans (Boulton and Fawcett). 1997;62:138-44

Population analysis of the pharmacokinetics and pharmacodynamics of seratroast in patients with mild to moderate asthma (Samara et al). 1997;62:426-35

Atiprimod dimaleate

Atiprimod dimaleate (USAN List No. 400). 1997;62:696

Avitriptan fumarate

Avitriptan fumarate (USAN List No. 395). 1997;62:115

B**Beta-endorphin**

Ibuprofen elevates immunoreactive β -endorphin levels in humans during surgical stress (Troullos et al). 1997;62:74-81

Bias

Bias against the null hypothesis in maternal-fetal pharmacology and toxicology (Koren). 1997;62:1-5 (Commentary)

Bile acids

Mephentoin disposition and serum bile acids as indexes of hepatic function in chronic viral hepatitis (Arns et al). 1997;62:527-37

Black Americans; see African Americans**BMS-181101; see Antidepressive agents****Bone marrow**

Olsalazine- and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction (Lewis et al). 1997;62:464-75

Brain injuries

Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries (Russo et al). 1997;62:15-20

Brain neoplasms

Anticonvulsant usage is associated with an increased risk of procainamide hypersensitivity reactions in patients with brain tumors (Lehmann et al). 1997;62:225-9

Brinzolamide

Brinzolamide (USAN List No. 396). 1997;62:236

Bronchoconstriction

Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval (Bronsky et al). 1997;62:556-61

Buprenorphine

Buprenorphine withdrawal syndrome in a newborn (Marquet et al). 1997;62:569-71

Buspirone

Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole (Kivistö et al). 1997;62:348-54

Butenafine hydrochloride

Butenafine hydrochloride (USAN List No. 396). 1997;62:236

C**Caffeine**

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Calculations

Computational results may depend on personal computer processor (Wakelkamp). 1997;62:481-2 (Commentary)

Candesartan

Candesartan (USAN List No. 400). 1997;62:696

Candesartan cilexetil

Candesartan cilexetil (USAN List No. 400). 1997;62:698

Carbamazepine

A randomized double-blind study of carbamazepine in the treatment of cocaine abuse (Halikas et al). 1997;62:89-105

Catecholamines

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Celgosivir hydrochloride

Celgosivir hydrochloride (USAN List No. 400). 1997;62:698

Central nervous system

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P450D6 inhibition in vivo (Özdemir et al). 1997;62:334-47

Cerebral injuries; see Brain injuries**Cevimeline hydrochloride**

Cevimeline hydrochloride (USAN List No. 399). 1997;62:580

CGP 51901

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis (Racine-Poon et al). 1997;62:675-90

Child; see also Infant, newborn

Arylamine *N*-acetyltransferase (NAT2) gene mutations in children with allergic diseases (Zielińska et al). 1997;62:635-42

Isoniazid acetylation metabolic ratio during maturation in children (Pariente-Khayat et al). 1997;62:377-83

Chimera

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis (Racine-Poon et al). 1997;62:675-90

Chloroguanide

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide (Jeppesen et al). 1997;62:279-86

Chlorzoxazone

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Cholesteryl ester transfer protein

Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine (Carrilho et al). 1997;62:82-8

Cholestyramine

Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine (Carrilho et al). 1997;62:82-8

Chronic renal failure; see Kidney failure

Cilmostim

Cilmostim (USAN List No. 400). 1997;62:699

Cilostazol

Cilostazol (USAN List No. 397). 1997;62:359

Circadian rhythm

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients (Prins et al). 1997;62:106-11

Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects (Srinivas et al). 1997;62:408-16

Citalopram

Using fuzzy logic to predict response to citalopram in alcohol dependence (Naranjo et al). 1997;62:209-24

Clinical Pharmacology & Therapeutics

Annual report to the Editorial Advisory Council, 1996 (Reidenberg and Reidenberg). 1997;62:230-2

Clinical trials

Drug load in clinical trials: a neglected factor (Deckers et al). 1997;62:592-5 (Commentary)

Clopidogrel bisulfate

Clopidogrel bisulfate (USAN List No. 398). 1997;62:478

Cocaine

A randomized double-blind study of carbamazepine in the treatment of cocaine abuse (Halikas et al). 1997;62:89-105

Colon

Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT₄ receptor agonist, in a model of slow colonic transit (Appel et al). 1997;62:546-55

Commentaries

Commentaries. 1997;62:1-5, 237-47, 361-4, 481-2, 583-95

Computers

Computational results may depend on personal computer processor (Wakelkamp). 1997;62:481-2 (Commentary)

Congestive heart failure; see Heart failure, congestive

Correspondence; see Letters

Cyclosporine

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses (Olbricht et al). 1997;62:311-21

Role of intestinal P-glycoprotein (*mdr1*) in interpatient variation in the oral bioavailability of cyclosporine (Lown et al). 1997;62:248-60

CYP1A2/CYP2C19/CYP2D6; see Cytochrome P450

Cysteine

Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval (Bronsky et al). 1997;62:556-61

Cytochrome P450

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects (Tybring et al). 1997;62:129-37

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide (Jeppesen et al). 1997;62:279-86

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy (Odani et al). 1997;62:287-92

Impact of long-term ethanol consumption on CYP1A2 activity (Rizzo et al). 1997;62:505-9

Induction of CYP2D6 in pregnancy (Wadelius et al). 1997;62:400-7

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants (Tran et al). 1997;62:490-504

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of 5-mephenytoin (Böttiger et al). 1997;62:384-91

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo (Özdemir et al). 1997;62:334-47

Role of intestinal P-glycoprotein (*mdr1*) in interpatient variation in the oral bioavailability of cyclosporine (Lown et al). 1997;62:248-60

Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (Donahue et al). 1997;62:572-7

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Cytokines

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers (Huhn et al). 1997;62:171-80

D

Daniplestim

Daniplestim (USAN List No. 399). 1997;62:581

Dapsone

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Debrisoquin

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Desipramine

The effect of sertraline on the pharmacokinetics of desipramine and imipramine (Kurtz et al). 1997;62:145-56

Desirudin

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin (Lefèvre et al). 1997;62:50-9

Dexamethasone

Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans (Jilma et al). 1997;62:562-8

Diabetes

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes (Sironi et al). 1997;62:194-202

Dialysis

In vivo drug-response measurements in target tissues by microdialysis (Müller et al). 1997;62:165-70

Diclofenac

Diclofenac concentrations in defined tissue layers after topical administration (Müller et al). 1997;62:293-9

Dipyrrone

Impairment of the metabolism of dipyrrone in asymptomatic carriers of the hepatitis B virus (Levy et al). 1997;62:6-14

Diuretics

Role of duration of diuretic effect in preventing sodium retention (Ferguson et al). 1997;62:203-8

Diurnal variation; see Circadian rhythm

Dopamine

Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure (Cotter et al). 1997;62:187-93

Drug abuse; see Substance abuse

Drug delivery systems

Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system (Ward et al). 1997;62:596-609

Drug development

Comparative regulation of drug and aircraft development: Lessons for regulatory reform? (Urquhart). 1997;62:583-6 (Commentary)

Drug dosage

Apparent decrease in population clearance of theophylline: implications for dosage (Asmus et al). 1997;62:483-9

Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval (Bronsky et al). 1997;62:556-61

Drug interactions

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses (Olbricht et al). 1997;62:311-21

Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine (Bergstrom et al). 1997;62:643-51

Drug load in clinical trials: a neglected factor (Deckers et al). 1997;62:592-5 (Commentary)

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers (Kazierad et al). 1997;62:417-25

The effect of sertraline on the pharmacokinetics of desipramine and imipramine (Kurtz et al). 1997;62:145-56

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of *S*-mephenytoin (Böttiger et al). 1997;62:384-91

Itraconazole increases plasma concentrations of quinidine (Kaukonen et al). 1997;62:510-7

Olsalazine- and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction (Lewis et al). 1997;62:464-75

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly (Jorga et al). 1997;62:300-10

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo (Özdemir et al). 1997;62:334-47

Plasma busiprone concentrations are greatly increased by erythromycin and itraconazole (Kivistö et al). 1997;62:348-54

Rifampin reduces plasma concentrations and effects of zolpidem (Vilikka et al). 1997;62:629-34

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole (Floren et al). 1997;62:41-9

Drug metabolism

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of *S*-mephenytoin (Sarich et al). 1997;62:21-8

Impairment of the metabolism of dipyrrone in asymptomatic carriers of the hepatitis B virus (Levy et al). 1997;62:6-14

Isoniazid acetylation metabolic ratio during maturation in children (Pariente-Khayat et al). 1997;62:377-83

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to *S*-mephenytoin 4'-hydroxylation phenotype and genotype (Tanaka et al). 1997;62:619-28

Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (Donahue et al). 1997;62:572-7

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Drug tolerance

Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance (Sütsch et al). 1997;62:538-45

Drug withdrawal syndrome; see Substance withdrawal syndrome

E**Ecamsule**

Ecamsule (USAN List No. 398). 1997;62:478

Education, medical

Birthing of clinical pharmacologists (Benowitz). 1997;62:587-91 (Commentary)

Clinical pharmacology education in primary care residency programs (Gray et al). 1997;62:237-40 (Commentary)

Elacridar hydrochloride

Elacridar hydrochloride (USAN List No. 399). 1997;62:582

Elderly; see Aged**Electroencephalography**

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalographic and saccadic eye movements in predicting improvement of sleep (Tuk et al). 1997;62:444-52

Endorphins

Ibuprofen elevates immunoreactive β -endorphin levels in humans during surgical stress (Troullos et al). 1997;62:74-81

Enzymes

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Eperezolid

Eperezolid (USAN List No. 399). 1997;62:580

Epilepsy

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy (Odani et al). 1997;62:287-92

Eplerenone

Eplerenone (USAN List No. 396). 1997;62:236

Eprosartan

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers (Kazierad et al). 1997;62:417-25

Erythromycin

Plasma busiprone concentrations are greatly increased by erythromycin and itraconazole (Kivistö et al). 1997;62:348-54

Ethanol; see Alcohol, ethyl

Ethnic factors

Vasodilation in black Americans: attenuated nitric oxide-mediated responses (Stein et al). 1997;62:436-43

Exercise

Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval (Bronsky et al). 1997;62:556-61

Eye movements

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalographic and saccadic eye movements in predicting improvement of sleep (Tuk et al). 1997;62:444-52

F

Fertilization in vitro

A population model for the follicular growth in women treated with follicle stimulating hormone (Karlsson et al). 1997;62:665-74

Fetus

Bias against the null hypothesis in maternal-fetal pharmacology and toxicology (Koren). 1997;62:1-5 (Commentary)

Fluconazole

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers (Kazierad et al). 1997;62:417-25

Fluoxetine

Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine (Bergstrom et al). 1997;62:643-51

Fluvoxamine

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide (Jeppesen et al). 1997;62:279-86

Follicle stimulating hormone

A population model for the follicular growth in women treated with follicle stimulating hormone (Karlsson et al). 1997;62:665-74

Forearm; see Arm

Furosemide

Furosemide does not prevent indomethacin-induced renal side effects in preterm infants (Romagnoli et al). 1997;62:181-6

Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure (Cotter et al). 1997;62:187-93

Fuzzy logic

Fuzzy logic pharmacokinetic modeling: application to lithium concentration prediction (Sproule et al). 1997;62:29-40

Using fuzzy logic to predict response to citalopram in alcohol dependence (Naranjo et al). 1997;62:209-24

G

Gadoxanum

Gadoxanum (USAN List No. 398). 1997;62:479

Gadozelite

Gadozelite (USAN List No. 398). 1997;62:479

Gender factors

Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects (Srinivas et al). 1997;62:408-16

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects (Wong et al). 1997;62:157-64

Genetics

Familial studies of heritability of α_1 -adrenergic receptor responsiveness in superficial veins (Gupta and Carruthers). 1997;62:322-6

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy (Odani et al). 1997;62:287-92

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms (Otterness et al). 1997;62:60-73

Genotype

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to *S*-mephenytoin 4'-hydroxylation phenotype and genotype (Tanaka et al). 1997;62:619-28

N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow? (O'Neil et al). 1997;62:261-71

Geriatrics; see Aged

Glycoproteins

Role of intestinal P-glycoprotein (*mdr1*) in interpatient variation in the oral bioavailability of cyclosporine (Lown et al). 1997;62:248-60

H

Hand

Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans (Masumori et al). 1997;62:327-33

Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance (Sütsch et al). 1997;62:538-45

Hay fever

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis (Racine-Poon et al). 1997;62:675-90

Heart

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes (Sironi et al). 1997;62:194-202

Heart failure, congestive

Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure (Cotter et al). 1997;62:187-93

Hefilcon C

Hefilcon C (USAN List No. 396). 1997;62:234

Hemodialysis

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis (Sica et al). 1997;62:610-8

Hemoglobin crosfumaryl

Hemoglobin crosfumaryl (USAN List No. 395). 1997;62:116

Hepatic function; see Liver

Hepatitis

Mephenytoin disposition and serum bile acids as indexes of hepatic function in chronic viral hepatitis (Arns et al). 1997;62:527-37

Hepatitis B virus

Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus (Levy et al). 1997;62:6-14

HIV

N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow? (O'Neil et al). 1997;62:261-71

5-HT₂; see Serotonin**Hydroxylation**

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to *S*-mephenytoin 4'-hydroxylation phenotype and genotype (Tanaka et al). 1997;62:619-28

Hypercholesterolemia

Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine (Carrilho et al). 1997;62:82-8

Hypersensitivity

Anticonvulsant usage is associated with an increased risk of procabazine hypersensitivity reactions in patients with brain tumors (Lehmann et al). 1997;62:225-9

Arylamine *N*-acetyltransferase (*NAT2*) gene mutations in children with allergic diseases (Zielińska et al). 1997;62:635-42

I**Ibuprofen**

Ibuprofen elevates immunoreactive β -endorphin levels in humans during surgical stress (Troullos et al). 1997;62:74-81

IgE

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis (Racine-Poon et al). 1997;62:675-90

Imipramine

The effect of sertraline on the pharmacokinetics of desipramine and imipramine (Kurtz et al). 1997;62:145-56

Immunoglobulin E; see IgE**Immunosuppression**

Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy (Hirano et al). 1997;62:652-64

Indinavir

Indinavir (USAN List No. 400). 1997;62:697

Indium In 111 pentetreotide

Indium In 111 pentetreotide (USAN List No. 398). 1997;62:479

Indomethacin

Furosemide does not prevent indomethacin-induced renal side effects in preterm infants (Romagnoli et al). 1997;62:181-6

Infant, newborn

Buprenorphine withdrawal syndrome in a newborn (Marquet et al). 1997;62:569-71

Tobramycin population pharmacokinetics in neonates (de Hoog et al). 1997;62:392-9

Infant, premature

Furosemide does not prevent indomethacin-induced renal side effects in preterm infants (Romagnoli et al). 1997;62:181-6

Insomnia

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalographic and saccadic eye movements in predicting improvement of sleep (Tuk et al). 1997;62:444-52

Insulin

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes (Sironi et al). 1997;62:194-202

Interferon-beta

Issues in pharmaceutical lotteries: the case of interferon beta-1b (Manocchia and Lasagna). 1997;62:241-7 (Commentary)

Interleukin-10

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers (Huhn et al). 1997;62:171-80

Internship and residency

Clinical pharmacology education in primary care residency programs (Gray et al). 1997;62:237-40 (Commentary)

Intestines

Role of intestinal P-glycoprotein (*mdr1*) in interpatient variation in the oral bioavailability of cyclosporine (Lown et al). 1997;62:248-60

Iobenguane I 131

Iobenguane I 131 (USAN List No. 399). 1997;62:581

Iobenguane sulfate I 131

Iobenguane sulfate I 131 (USAN List No. 397). 1997;62:359

Iocanlidic acid I 123

Iocanlidic acid I 123 (USAN List No. 400). 1997;62:697

Iometopane I 123

Iometopane I 123 (USAN List No. 397). 1997;62:358

Irbesartan

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis (Sica et al). 1997;62:610-8

Isoniazid

Isoniazid acetylation metabolic ratio during maturation in children (Pariente-Khayat et al). 1997;62:377-83

Isotretinoin anisatril

Isotretinoin anisatril (USAN List No. 396). 1997;62:235

Itraconazole

Itraconazole increases plasma concentrations of quinidine (Kaukonen et al). 1997;62:510-7

Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole (Kivistö et al). 1997;62:348-54

J**Japan**

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy (Odani et al). 1997;62:287-92

Journal

Annual report to the Editorial Advisory Council, 1996 (Reidenberg and Reidenberg). 1997;62:230-2

K**Ketoconazole**

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of *S*-mephenytoin (Böttiger et al). 1997;62:384-91

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole (Floren et al). 1997;62:41-9

Kidney

Aging effects on the organic base transporter and stereoselective renal clearance (Ujhelyi et al). 1997;62:117-28

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients (Prins et al). 1997;62:106-11

Furosemide does not prevent indomethacin-induced renal side effects in preterm infants (Romagnoli et al). 1997;62:181-6

Kidney failure

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin (Lefèvre et al). 1997;62:50-9

Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy (Hirano et al). 1997;62:652-64

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis (Sica et al). 1997;62:610-8

Kidney transplantation

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses (Olbricht et al). 1997;62:311-21

L

Lanotepase

Lanotepase (USAN List No. 400). 1997;62:700

Legislation, drug

Comparative regulation of drug and aircraft development: Lessons for regulatory reform? (Urquhart). 1997;62:583-6 (Commentary)

Letters

Direct evidence for the higher frequency of *CYP2C19* allelic heterozygotes in Chinese subjects than in white subjects (Xie). 1997;62:691-2

Informing the public (Weiner) (Letter); (Spence) (Reply). 1997;62:578-9

Reliability of screening procedures in identifying subjects suitable for enrollment in clinical pharmacology studies (de Mey) (Letter); (Apseloff et al) (Reply). 1997;62:112-4

Self-medication (Casner). 1997;62:355

Toxicity of lidocaine desethyl metabolites (Walson). 1997;62:579

Leukotrienes

Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval (Bronsky et al). 1997;62:556-61

Levodopa

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly (Jorga et al). 1997;62:300-10

Linezolid

Linezolid (USAN List No. 399). 1997;62:582

Lithium

Fuzzy logic pharmacokinetic modeling: application to lithium concentration prediction (Sproule et al). 1997;62:29-40

Liver

Mefenytin disposition and serum bile acids as indexes of hepatic function in chronic viral hepatitis (Arns et al). 1997;62:527-37

Pharmacokinetics of valsartan in patients with liver disease (Brookman et al). 1997;62:272-8

Logic

Fuzzy logic pharmacokinetic modeling: application to lithium concentration prediction (Sproule et al). 1997;62:29-40

Using fuzzy logic to predict response to citalopram in alcohol dependence (Naranjo et al). 1997;62:209-24

Losartan

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers (Kazierad et al). 1997;62:417-25

Lovastatin

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses (Olbricht et al). 1997;62:311-21

L-selectin

Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans (Jilma et al). 1997;62:562-8

Lubeluzole

Lubeluzole (USAN List No. 400). 1997;62:697

Lymphocytes

Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans (Jilma et al). 1997;62:562-8

Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy (Hirano et al). 1997;62:652-64

M

Maternal-fetal exchange

Bias against the null hypothesis in maternal-fetal pharmacology and toxicology (Koren). 1997;62:1-5 (Commentary)

Medical oncology

Geriatric clinical pharmacologist and medical oncologist: A new partnership? (Vestal and Calabresi). 1997;62:361-4 (Commentary)

Mefenytin

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of *S*-mefenytin (Sarich et al). 1997;62:21-8

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of *S*-mefenytin (Böttiger et al). 1997;62:384-91

Mefenytin disposition and serum bile acids as indexes of hepatic function in chronic viral hepatitis (Arns et al). 1997;62:527-37

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to *S*-mefenytin 4'-hydroxylation phenotype and genotype (Tanaka et al). 1997;62:619-28

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Frye et al). 1997;62:365-76

Mercaptopurine

Olsalazine- and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction (Lewis et al). 1997;62:464-75

Microdialysis; see Dialysis

Modeling

Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT₄ receptor agonist, in a model of slow colonic transit (Appel et al). 1997;62:546-55

Fuzzy logic pharmacokinetic modeling: application to lithium concentration prediction (Sproule et al). 1997;62:29-40

A population model for the follicular growth in women treated with follicle stimulating hormone (Karlsson et al). 1997;62:665-74

Monoclonal antibodies; see Antibodies, monoclonal

Montelukast

Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval (Bronsky et al). 1997;62:556-61

Morphine

Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system (Ward et al). 1997;62:596-609

Multiple sclerosis

Issues in pharmaceutical lotteries: the case of interferon beta-1b (Manocchia and Lasagna). 1997;62:241-7 (Commentary)

Muscle

In vivo drug-response measurements in target tissues by microdialysis (Müller et al). 1997;62:165-70

Mutation

Arylamine *N*-acetyltransferase (*NAT2*) gene mutations in children with allergic diseases (Zielińska et al). 1997;62:635-42

N

N-acetylation; *see* **Acetylation**

Nasal spray; *see* **Administration, nasal**

Nelficon A

Nelficon A (USAN List No. 396). 1997;62:234

Neonate; *see* **Infant, newborn**

Neoplasms

Geriatric clinical pharmacologist and medical oncologist: A new partnership? (Vestal and Calabresi). 1997;62:361-4 (Commentary)

Nephrosis

Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy (Hirano et al). 1997;62:652-64

Neutrophils

Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans (Jilma et al). 1997;62:562-8

Nicotine

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Nitric oxide

Vasodilation in black Americans: attenuated nitric oxide-mediated responses (Stein et al). 1997;62:436-43

Nitroglycerin

Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance (Sütsch et al). 1997;62:538-45

O

Olsalazine

Olsalazine- and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction (Lewis et al). 1997;62:464-75

Omeprazole

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of *S*-mephenytoin (Sarich et al). 1997;62:21-8

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects (Tybring et al). 1997;62:129-37

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of *S*-mephenytoin (Böttiger et al). 1997;62:384-91

Organic base transporter

Aging effects on the organic base transporter and stereoselective renal clearance (Ujhelyi et al). 1997;62:117-28

P

Pain

Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system (Ward et al). 1997;62:596-609

Pantoprazole

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to *S*-mephenytoin 4'-hydroxylation phenotype and genotype (Tanaka et al). 1997;62:619-28

Paroxetine

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo (Özdemir et al). 1997;62:334-47

Perphenazine

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo (Özdemir et al). 1997;62:334-47

P-glycoproteins; *see* **Glycoproteins**

Pharmaceutical lotteries

Issues in pharmaceutical lotteries: the case of interferon beta-1b (Manocchia and Lasagna). 1997;62:241-7 (Commentary)

Pharmacogenetics; *see* **Genetics**

Pharmacology, clinical

Birthing of clinical pharmacologists (Benowitz). 1997;62:587-91 (Commentary)

Geriatric clinical pharmacologist and medical oncologist: A new partnership? (Vestal and Calabresi). 1997;62:361-4 (Commentary)

Phenotype

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to *S*-mephenytoin 4'-hydroxylation phenotype and genotype (Tanaka et al). 1997;62:619-28

N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow? (O'Neil et al). 1997;62:261-71

Phenytoin

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy (Odani et al). 1997;62:287-92

Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (Donahue et al). 1997;62:572-7

Plasma

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Itraconazole increases plasma concentrations of quinidine (Kaukonen et al). 1997;62:510-7

Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole (Kivistö et al). 1997;62:348-54

Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine (Carrilho et al). 1997;62:82-8

Rifampin reduces plasma concentrations and effects of zolpidem (Villikka et al). 1997;62:629-34

Poisoning

Bias against the null hypothesis in maternal-fetal pharmacology and toxicology (Koren). 1997;62:1-5 (Commentary)

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients (Prins et al). 1997;62:106-11

Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure (Cotter et al). 1997;62:187-93

Polymorphism

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms (Ottemess et al). 1997;62:60-73

Population studies

Apparent decrease in population clearance of theophylline: implications for dosage (Asmus et al). 1997;62:483-9

Population analysis of the pharmacokinetics and pharmacodynamics of seratrodist in patients with mild to moderate asthma (Samara et al). 1997;62:426-35

A population model for the follicular growth in women treated with follicle stimulating hormone (Karlsson et al). 1997;62:665-74

Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries (Russo et al). 1997;62:15-20
Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis (Bruno et al). 1997;62:518-26
Tobramycin population pharmacokinetics in neonates (de Hoog et al). 1997;62:392-9

Pravastatin

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses (Olbricht et al). 1997;62:311-21

Pregnancy

Bias against the null hypothesis in maternal-fetal pharmacology and toxicology (Koren). 1997;62:1-5 (Commentary)
Induction of CYP2D6 in pregnancy (Wadelius et al). 1997;62:400-7

Preterm infant; see Infant, premature

Primary health care

Clinical pharmacology education in primary care residency programs (Gray et al). 1997;62:237-40 (Commentary)

Procarbazine

Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors (Lehmann et al). 1997;62:225-9

Psoriasis

Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy (Hirano et al). 1997;62:652-64

Pulmonary administration; see Administration, inhalation

Q

Quinidine

Itraconazole increases plasma concentrations of quinidine (Kaukonen et al). 1997;62:510-7

R

Receptors, adrenergic, alpha

Familial studies of heritability of α_1 -adrenergic receptor responsiveness in superficial veins (Gupta and Carruthers). 1997;62:322-6

Regulation, drug; see Legislation, drug

Renal impairment; see Kidney failure

Residency; see Internship and residency

Reteplase

Reteplase (USAN List No. 397). 1997;62:360

Rifampin

Rifampin reduces plasma concentrations and effects of zolpidem (Villikka et al). 1997;62:629-34

Riluzole

Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis (Bruno et al). 1997;62:518-26

S

Saccades

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalographic and saccadic eye movements in predicting improvement of sleep (Tuk et al). 1997;62:444-52

Salts

Role of duration of diuretic effect in preventing sodium retention (Ferguson et al). 1997;62:203-8

SDZ HTF 919

Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT₄ receptor agonist, in a model of slow colonic transit (Appel et al). 1997;62:546-55

Seasonal allergic rhinitis; see Hay fever

Seratrodist

Population analysis of the pharmacokinetics and pharmacodynamics of seratrodist in patients with mild to moderate asthma (Samara et al). 1997;62:426-35

Serotonin

Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT₄ receptor agonist, in a model of slow colonic transit (Appel et al). 1997;62:546-55

Sertindole

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects (Wong et al). 1997;62:157-64

Sertraline

The effect of sertraline on the pharmacokinetics of desipramine and imipramine (Kurtz et al). 1997;62:145-56

Sildenafil citrate

Sildenafil citrate (USAN List No. 397). 1997;62:358

Skin

In vivo drug-response measurements in target tissues by microdialysis (Müller et al). 1997;62:165-70

Sleep disorders

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalographic and saccadic eye movements in predicting improvement of sleep (Tuk et al). 1997;62:444-52

S-mephenytoin; see Mephenytoin

Smoking

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Sodium

Role of duration of diuretic effect in preventing sodium retention (Ferguson et al). 1997;62:203-8

Software

Computational results may depend on personal computer processor (Wakelkamp). 1997;62:481-2 (Commentary)

Stiripentol

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants (Tran et al). 1997;62:490-504

Substance abuse

A randomized double-blind study of carbamazepine in the treatment of cocaine abuse (Halikas et al). 1997;62:89-105

Substance withdrawal syndrome

Buprenorphine withdrawal syndrome in a newborn (Marquet et al). 1997;62:569-71

Surgery

Ibuprofen elevates immunoreactive β -endorphin levels in humans during surgical stress (Troullos et al). 1997;62:74-81

Sweden

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects (Tybring et al). 1997;62:129-37

T

Tacrolimus

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole (Floren et al). 1997;62:41-9

Telmisartan

Telmisartan (USAN List No. 399). 1997;62:581

Temazepam

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalographic and saccadic eye movements in predicting improvement of sleep (Tuk et al). 1997;62:444-52

Terfenadine

Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine (Bergstrom et al). 1997;62:643-51

Theophylline

Apparent decrease in population clearance of theophylline: implications for dosage (Asmus et al). 1997;62:483-9

Thiopental

Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries (Russo et al). 1997;62:15-20

Thiopurine

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms (Otterness et al). 1997;62:60-73

Tiagabine hydrochloride

Tiagabine hydrochloride (USAN List No. 396). 1997;62:233

Ticlopidine

Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (Donahue et al). 1997;62:572-7

Ticolubant

Ticolubant (USAN List No. 395). 1997;62:116

T-lymphocytes

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers (Huhn et al). 1997;62:171-80

Tobramycin

Tobramycin population pharmacokinetics in neonates (de Hoog et al). 1997;62:392-9

Tolcapone

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly (Jorga et al). 1997;62:300-10

Tolerance; see Drug tolerance**Topical administration; see Administration, topical****Toxicity; see Poisoning****Trimegestone**

Trimegestone (USAN List No. 395). 1997;62:116

Troglitazone

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes (Sironi et al). 1997;62:194-202

Tumor necrosis factor

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers (Huhn et al). 1997;62:171-80

U

United States Adopted Names Council

USAN Council. 1997;62:115-6, 233-6, 358-60, 478-9, 580-2, 696-700

V

Valsartan

Pharmacokinetics of valsartan in patients with liver disease (Brookman et al). 1997;62:272-8

Vasoconstriction

Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans (Masumori et al). 1997;62:327-33

Vasodilation

Vasodilation in black Americans: attenuated nitric oxide-mediated responses (Stein et al). 1997;62:436-43

Veins

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine (Gourlay and Benowitz). 1997;62:453-63

Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans (Masumori et al). 1997;62:327-33

Familial studies of heritability of α_1 -adrenergic receptor responsiveness in superficial veins (Gupta and Carruthers). 1997;62:322-6

Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance (Sütsch et al). 1997;62:538-45

Z

Zolmitriptan

Zolmitriptan (USAN List No. 395). 1997;62:116

Zolpidem

Rifampin reduces plasma concentrations and effects of zolpidem (Villikka et al). 1997;62:629-3

